Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9018657 | 0.87 | MEN1 (0.71) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL20941638 | 0.85 | SAE1 (0.62) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL20379476 | 0.84 | KMT2A (0.66) | MEN1KMT2AMAPTTHRBLMNA | |
| SCHEMBL6162468 | 0.83 | ALDH1A1 (0.62) | MEN1KMT2AMAPTTHRBLMNA | |
| SCHEMBL1552887 | 0.81 | MAPT (0.52) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL2336524 | 0.81 | CA12 (0.60) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL57257 | 0.80 | VCAM1 (0.61) | MEN1KMT2AMAPTTHRBLMNA | |
| SCHEMBL16089350 | 0.80 | VCAM1 (0.61) | MEN1KMT2AMAPTTHRBLMNA | |
| SCHEMBL3677488 | 0.79 | MEN1 (0.65) | MEN1KMT2AMAPTLMNAHTT | |
| Selenium SCHEMBL9497333 | 0.78 | VCAM1 (0.59) | MEN1KMT2AMAPTTHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731946-B2 | Broad spectrum antivirulence, anti-persistence compounds | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731946-B2 | Broad spectrum antivirulence, anti-persistence compounds | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210130306-A1 | BROAD SPECTRUM ANTIVIRULENCE, ANTI-PERSISTENCE COMPOUNDS | THE GENERAL HOSPITAL CORPORATION | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731946-B2 | Broad spectrum antivirulence, anti-persistence compounds | ME2, ME1, ME3 | MEN1 3416/4885KMT2A 1458/4885MAPT 2412/4885 |
| US-20210130306-A1 | BROAD SPECTRUM ANTIVIRULENCE, ANTI-PERSISTENCE COMPOUNDS | ME2, ME1, ME3 | MEN1 3416/4885KMT2A 1458/4885MAPT 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.